AbbVie joined the 10 % price - hike pledge on Wednesday, following Allergan and Novo Nordisk, as
the drug pricing debate sent biopharma shares reeling once again.
JPMorgan health care expert Lisa Gill shared her thoughts on the hotly - followed
drug pricing debate as well as potential stock picks.
Not exact matches
The
debate over high
drug prices has been a red hot topic here and inspired a lot of anger and legislative threats, especially in the midst of the 2016 election cycle.
It aggressively ratcheted up spending to spread its influence in Washington and to have a louder say in the
debates over
drug prices.
But as these recent fiery
debates within the
drug industry underscore, pharma's
price hike tactics, now under constant public scrutiny, may well lead to more far - reaching change — whether imposed by legislation or by biopharma companies upon themselves.
PBMs have come into the spotlight in the
debate over soaring
drug prices, with manufacturers accusing them of contributing to inflating costs.
Biotech stocks slumped Tuesday ahead of the Democratic presidential
debate on speculation that candidates will call for measures to limit
drug -
price increases.
There is, of course, a never - ending
debate about the ethics of
drug pricing.
Key market issues such as
drug pricing and breaking up the banks were not discussed at this
debate.
Questions - Sure Start closures, food
prices, cancer
drug fund, BSkyB takeover bid Legislation - health and social care bill
Debate - competitiveness of the UK egg industry